Skip to main content

Table 1 Baseline Characteristics of Non-OAC and OAC Cohorts

From: Changes in primary care management of atrial fibrillation patients following the shift from warfarin to non-vitamin K antagonist oral anticoagulants: a Norwegian population based study

Variable

Overall

Non-OAC

OAC

SMD

n

92,936

28,824

64,112

 

Female, n (%)

40,960 (44.1)

13,317 (46.2)

27,643 (43.1)

0.062

Mean Age (SD)

71.31 (13.46)

67.66 (16.93)

72.95 (11.19)

0.368

Concomitant medication (1-year preceding index to 120 days post index), n (%)

 NSAID

24,623 (26.5)

8374 (29.1)

16,249 (25.3)

0.083

 Anti-platelet treatment, including low-dose aspirin

47,108 (50.7)

14,218 (49.3)

32,890 (51.3)

0.039

 Per-oral antidiabetic drugs

8482 (9.1)

1825 (6.3)

6657 (10.4)

0.147

 Acid secretory drugs

25,861 (27.8)

7972 (27.7)

17,889 (27.9)

0.005

 Heparin

5475 (5.9)

1625 (5.6)

3850 (6.0)

0.016

 Anti-arrhythmic drugs class iii

6355 (6.8)

1268 (4.4)

5087 (7.9)

0.147

 Anti-hypertensives

2049 (2.2)

422 (1.5)

1627 (2.5)

0.077

 Diuretics

28,519 (30.7)

6829 (23.7)

21,690 (33.8)

0.225

 Beta-blockers

67,830 (73.0)

16,848 (58.5)

50,982 (79.5)

0.468

 Calcium antagonists

25,991 (28.0)

6507 (22.6)

19,484 (30.4)

0.178

 Renin-angiotensin system drugs

46,452 (50.0)

10,330 (35.8)

36,122 (56.3)

0.420

 Lipid-modifying drugs

39,870 (42.9)

9505 (33.0)

30,365 (47.4)

0.297

 Insulin

2968 (3.2)

672 (2.3)

2296 (3.6)

0.074

Medical history (4 years preceding index), n (%)

 Alcoholism

1330 (1.4)

630 (2.2)

700 (1.1)

0.086

 Chronic kidney disease

4088 (4.4)

1344 (4.7)

2744 (4.3)

0.019

 Congestive heart failure

7703 (8.3)

2625 (9.1)

5078 (7.9)

0.043

 Hypertension

46,280 (49.8)

11,825 (41.0)

34,455 (53.7)

0.257

 Liver disease

911 (1.0)

350 (1.2)

561 (0.9)

0.033

 Stroke

6588 (7.1)

1884 (6.5)

4704 (7.3)

0.032

 Transient ischaemic attack

3863 (4.2)

1081 (3.8)

2782 (4.3)

0.030

 Myocardial infarction

2797 (3.0)

910 (3.2)

1887 (2.9)

0.012

 Angina Pectoris

8498 (9.1)

2617 (9.1)

5881 (9.2)

0.003

 Peripheral artery disease

3077 (3.3)

854 (3.0)

2223 (3.5)

0.029

 Pulmonary embolism

554 (0.6)

177 (0.6)

377 (0.6)

0.003

 Prior major bleeding (critical organ)

6370 (6.9)

2325 (8.1)

4045 (6.3)

0.068

 Type 2 diabetes

12,501 (13.5)

2856 (9.9)

9645 (15.0)

0.156

 Dementia

2207 (2.4)

1167 (4.0)

1040 (1.6)

0.147

 COPD

7989 (8.6)

2362 (8.2)

5627 (8.8)

0.021

 Connective tissue disease

7234 (7.8)

2374 (8.2)

4860 (7.6)

0.024

 Leukaemia

273 (0.3)

86 (0.3)

187 (0.3)

0.001

 Lymphoma

720 (0.8)

264 (0.9)

456 (0.7)

0.023

 Solid tumour

13,090 (14.1)

4126 (14.3)

8964 (14.0)

0.010

Risk scores, mean (SD)

 CHA2dsVASc men

1.97 (1.44)

1.58 (1.51)

2.14 (1.37)

0.394

 CHA2dsVASc women

3.44 (1.41)

3.13 (1.58)

3.59 (1.29)

0.319

 Modified HAS-BLED Score

2.04 (1.06)

1.81 (1.14)

2.14 (1.01)

0.301

 Co-Morbidity Index

4.45 (2.04)

4.10 (2.36)

4.61 (1.85)

0.241

  1. Abbreviations: COPD Chronic obstructive pulmonary disease, NSAID Non-steroidal anti-inflammatory drug, OAC Oral anticoagulant, SD Standard deviation, SMD Standardised mean difference